Portfolio Update

Finsbury Worldwide Pharm Tst PLC 05 July 2006 5 July 2006 FINSBURY WORLDWIDE PHARMACEUTICAL TRUST PLC (the 'Company') QUARTERLY STATEMENT OF INVESTMENTS In compliance with the Listing Rules - Chapter 21 Investment Entities (I)(ii), the Company discloses the following: • Investments valuing greater than 5% of the Company's gross assets comprise the following: Company Name Value of Investment at % of Total Portfolio Assets 30 June 2006 NOVARTIS CHF0.50 REGD 29,050,294 8.75 GENENTECH INC COM STK USD0.02 NPV 21,671,217 6.53 AMGEN COM USD0.0001 17,351,875 5.23 LILLY (ELI) & COMPANY COM USD NPV 17,182,693 5.18 WYETH COM USD0.333 17,096,007 5.15 • The ten largest investments held by the Company comprise the following: Company Name Value of Investment at % of Total Portfolio Assets 30 June 2006 NOVARTIS CHF0.50 REGD 29,050,294 8.75 GENENTECH INC COM STK USD0.02 NPV 21,671,217 6.53 AMGEN COM USD0.0001 17,351,875 5.23 LILLY (ELI) & COMPANY COM USD NPV 17,182,693 5.18 WYETH COM USD0.333 17,096,007 5.15 JOHNSON & JOHNSON COM USD1 15,744,976 4.75 SERONO SA 'B' CHF25 14,909,300 4.49 GEN-PROBE INC USD0.0001 14,300,884 4.31 PFIZER COM USD0.05 13,222,535 3.98 TAKEDA PHARAMACEUTICAL CO NPV 13,059,561 3.94 - ENDS - For further information please contact: Tracey Lago, Senior Company Secretary Close Finsbury Asset Management Limited Telephone: 020 7426 6219 This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings